PHAXIAM Therapeutics: Postponement of the Offer Review Hearing
22 Mai 2025 - 6:00PM
Business Wire
Regulatory News:
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a
biopharmaceutical company ("the Company" or "PHAXIAM") developing
innovative treatments for severe and resistant bacterial
infections, announces that the Lyon Commercial Court (“Tribunal des
activités économiques de Lyon”) decided, during a hearing held on
May 21, 2025, to postpone the offer review hearing and has set a
new hearing date for Wednesday, June 4, 2025.
At the end of the bid examination hearing, whether a bid is
accepted or not, the Lyon Commercial Court will in any case soon
pronounce the conversion of the judicial reorganization into
judicial liquidation. In this context, the Company will request the
delisting of PHAXIAM shares from Euronext.
Furthermore, PHAXIAM draws investors’ attention to the fact
that, given the Company’s level of indebtedness, the disposal
proceeds received in the event a bid is adopted will likely not
allow for any reimbursement of shareholders.
About PHAXIAM Therapeutics
PHAXIAM is a biopharmaceutical company developing innovative
treatments for resistant bacterial infections, which are
responsible for many serious infections. The company is building on
an innovative approach based on the use of phages, natural
bacteria-killing viruses. PHAXIAM is developing a portfolio of
phages targeting 3 of the most resistant and dangerous bacteria,
which together account for more than two-thirds of resistant
hospital-acquired infections: Staphylococcus aureus, Escherichia
coli and Pseudomonas aeruginosa.
PHAXIAM is listed on the Euronext regulated market in Paris
(ISIN code: FR001400K4B1, ticker: PHXM). PHAXIAM is part of the CAC
Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All
Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
For more information, please visit www.phaxiam.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250522999893/en/
PHAXIAM Thibaut du Fayet CEO +33 4 78 74 44 38
investors@phaxiam.com
NewCap Mathilde Bohin / Dušan Orešanský Investor
Relations Arthur Rouillé Media Relations +33 1 44 71 94 94
phaxiam@newcap.eu
PHAXIAM Therapeutics (EU:PHXM)
Graphique Historique de l'Action
De Juin 2025 à Juil 2025
PHAXIAM Therapeutics (EU:PHXM)
Graphique Historique de l'Action
De Juil 2024 à Juil 2025